For decades, the "holy grail" in genetic medicine has been simple: how do you get therapies into the bloodstream to reach targets beyond the liver? But if you ask most people what the core issue is, you get a hand-wavy, incomplete answer: "delivery."

Jake Becraft, CEO of Strand Therapeutics, calls that a "cheap answer." It's not wrong, he says, but it’s a massive oversimplification. Becraft, whose company is pioneering RNA genetic medicines (including a recent case that saw a Stage 4 melanoma patient achieve remission via the abscopal effect), argues that the problem isn't one thing. It's three distinct challenges hiding in plain sight. Becraft described it as "three children in their father's trench coat pretending to be an adult." When you pull back the coat, you don't find a single solution. You find a trio of intertwined problems: potency, specificity, and the actual transport mechanism.

Key Takeaways

  • For 30 years, the genetic medicine field has chased the "holy grail" of effective intravenous (IV) delivery to tissues beyond the liver.
  • The common answer—that "delivery" is the problem—is a convenient but incomplete explanation, according to Jake Becraft.
  • Becraft asserts that "delivery" is actually three interdependent challenges: making the medicine strong enough (potency), ensuring it hits the right cells (specificity), and physically moving it there (delivery).
  • Strand Therapeutics' core mission wasn't just to build a first drug, but to solve this multi-layered problem, which has remained a big question mark for decades.
  • The Three Core Problems of Genetic Medicine Delivery framework redefines how we approach these complex therapeutic challenges.

The Three Core Problems of Genetic Medicine Delivery

  • Problem 1: Potency: Making the medicine strong enough to have the desired biological effect.
  • Problem 2: Specificity: Ensuring the medicine reaches and acts only on the intended cells or tissues, avoiding off-target effects.
  • Problem 3: Delivery: The actual transport mechanism to get the genetic medicine to the desired location in the body.

When This Works (and When It Doesn't)

This framework clarifies the complex challenge of genetic medicine delivery, moving beyond the simplistic notion that 'delivery' is a single problem. By breaking it down into potency, specificity, and delivery, it guides innovators to address each interdependent component for effective and safe therapeutic application throughout the body, not just the liver. It shines when you are tackling a problem that seems singular but is actually a choke point for multiple underlying issues. However, it's less useful if your problem truly is one-dimensional, or if breaking it down further introduces unnecessary complexity where the sub-problems don't have strong interdependencies.

What to Do With This

Next time you hear someone — or yourself — say your startup's big challenge is "user acquisition" or "product-market fit," stop. Jake Becraft's insight suggests that's a trench coat answer. Take your "big problem" and apply his framework. For example, if your challenge is "user acquisition," break it down: Is it a potency problem (is your offer compelling enough to grab attention in a crowded market)? Is it a specificity problem (are you targeting the exact right segment of users with tailored messaging, or casting too wide a net)? Or is it a pure delivery problem (are your ads reaching the right channels, or is your landing page broken)? Pinpointing which of the three is weakest—or how they interact—will immediately give you a more actionable path forward than just vaguely trying to "fix acquisition."